Scientists hope to begin clinical tests of a new anti-viral drug which has had positive results in laboratory tests against Covid-19.
Pneumagen, a spin-out company from St Andrews University, carried out three separate studies into preventing coronavirus infections.
The successful studies involved both treating infection and blocking new infections.
Working closely with Public Health England’s Porton facility and, separately, Glasgow University’s MRC Centre for Virus Research, Pneumagen tested the activity of its creations against coronaviruses.
At both Porton and Glasgow University of Glasgow, the number of Sars-CoV-2 plaques were reduced in both prevention and treatment of infection.
Pneumagen now wants to begin clinical testing for the prevention and treatment of Covid-19.
‘Our goal is now to rapidly begin clinical testing for the prevention and treatment of Covid-19.’
Chief executive Douglas Thomson
Chief executive Douglas Thomson said: “Today’s positive results from in-vitro studies of our mCBMs against coronaviruses show that glycan binding has the potential to prevent and treat infection.
“Our goal is now to rapidly begin clinical testing for the prevention and treatment of Covid-19.”
Follow STV News on WhatsApp
Scan the QR code on your mobile device for all the latest news from around the country
